Interpace Diagnostics

Interpace Diagnostics is a healthcare commercialization company providing go-to-market strategy and execution to established and emerging pharmaceutical, biotechnology, diagnostics and healthcare companies in the United States. The company operates a molecular diagnostics company that helps physicians better manage patients at risk for certain types of gastrointestinal cancers through its proprietary PathFinderTG platform. Its PathfinderTG platform uses advanced clinical algorithms to accurately stratify patients according to risk of cancer by assessing panels of DNA abnormalities in patients who have lesions (i.e., cysts or solid masses) with potential for cancer.
Type
Public
HQ
Parsippany Troy Hills, US
Founded
1987
Size (employees)
65 (est)
Interpace Diagnostics was founded in 1987 and is headquartered in Parsippany-Troy Hills, US

Interpace Diagnostics Office Locations

Interpace Diagnostics has an office in Parsippany-Troy Hills
Parsippany Troy Hills, US (HQ)
300 Interpace Pkwy

Interpace Diagnostics Data and Metrics

Interpace Diagnostics Financial Metrics

Interpace Diagnostics's revenue was reported to be $9.4 m in FY, 2015 which is a 92% decrease from the previous period.
Numbers are in $, USD

Revenue (FY, 2015)

9.4 m

Revenue growth (FY, 2014 - FY, 2015), %

(92%)

Gross profit (FY, 2015)

2.5 m

Gross profit margin (FY, 2015), %

27%

Net income (FY, 2015)

(11.4 m)

EBIT (FY, 2015)

(40.4 m)

Market capitalization (26-May-2017)

12 m

Closing share price (26-May-2017)

1.9

Cash (31-Dec-2015)

8.3 m

EV

12.1 m
Interpace Diagnostics's current market capitalization is $12 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015

Revenue

150.8 m119.9 m9.4 m

Revenue growth, %

(20%)(92%)

Cost of goods sold

126.4 m101.4 m6.9 m

Gross profit

24.4 m18.5 m2.5 m

Gross profit Margin, %

16%15%27%

Operating expense total

28.7 m32 m42.9 m

EBIT

(4.3 m)(13.5 m)(40.4 m)

EBIT margin, %

(3%)(11%)(428%)

Interest expense

602 k3.7 m

Net Income

(4.6 m)(16.1 m)(11.4 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015

Cash

45.6 m23.1 m8.3 m

Accounts Receivable

2.4 m8.5 m2.8 m

Current Assets

62.7 m44.9 m19.2 m

PP&E

2.8 m3.2 m1.5 m

Goodwill

2.5 m15.5 m

Total Assets

69.1 m115.9 m67.7 m

Accounts Payable

2.4 m4.3 m1.6 m

Total Debt

27.2 m8.4 m

Current Liabilities

31.4 m33.6 m23.4 m

Additional Paid-in Capital

130.2 m134.2 m132.5 m

Retained Earnings

(83.8 m)(99.9 m)(111.3 m)

Total Equity

32.5 m20.1 m13 m

Debt to Equity Ratio

1.3 x0.6 x

Debt to Assets Ratio

0.2 x0.1 x

Financial Leverage

2.1 x5.8 x5.2 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015

Net Income

(4.6 m)(16.1 m)(11.4 m)

Cash From Operating Activities

(3.5 m)(16.4 m)(19.8 m)

Purchases of PP&E

(1.8 m)(2.9 m)(353 k)

Cash From Investing Activities

(3.3 m)(25.4 m)26.4 m

Cash From Financing Activities

(314 k)19.2 m(21.4 m)

Income Taxes Paid

235 k115 k242 k
Numbers are in $, USDY, 2015

EV/EBIT

-0.3 x

EV/CFO

-0.6 x

Revenue/Employee

12.2 k

Debt/Equity

0.6 x

Debt/Assets

0.1 x

Financial Leverage

5.2 x

Interpace Diagnostics Operating Metrics

FY, 2016

Facilities

2

Patents (foreign)

3

Products

3

Patents (US)

1

Patent Applications

16

Interpace Diagnostics Market Value History

Interpace Diagnostics Online and Social Media Presence

Interpace Diagnostics Company Life and Culture

You may also be interested in